KRAS and colorectal carcinoma: Adagrasib monotherapy for pretreated KRAS G12C mutated advanced CRC was evaluated in KRYSTAL-1, where 44 patients with CRC received adagrasib monotherapy, and an ORR of 19% with mPFS of 5.6 months was reported [10].